| Literature DB >> 34980008 |
Ilko L Maier1, Gerrit U Herpertz2, Mathias Bähr3, Marios-Nikos Psychogios4, Jan Liman3.
Abstract
BACKGROUND: Transient ischemic attack (TIA) is an important predictor for a pending stroke. Guidelines recommend a workup for TIA-patients similar to that of stroke patients, including an assessment of the extra- and intracranial arteries for vascular pathologies with direct therapeutic implications via computed tomography angiography (CTA). Aim of our study was a systematic analysis of TIA-patients receiving early CTA-imaging and to evaluate the predictive value of TIA-scores and clinical characteristics for ipsilateral vascular pathologies and the need of an invasive treatment.Entities:
Mesh:
Year: 2022 PMID: 34980008 PMCID: PMC8722154 DOI: 10.1186/s12883-021-02523-y
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Fig. 1Inclusion flow chart
Baseline characteristics of TIA-patients with- and without ipsilateral vascular pathology and the need for invasive treatment (n = 812)
| No ipsilateral vascular pathology ( | Ipsilateral vascular pathology ( | No invasive treatment ( | Invasive treatment ( | |||
|---|---|---|---|---|---|---|
| Demographic data | ||||||
| Age, years ± SD | 71 ± 14 | 71 ± 13 | 0.760 | 71 ± 14 | 68 ± 11 | 0.165 |
| Sex (male, %) | 365 (52.8) | 78 (64.5) | 0.018 | 420 (54.1) | 23 (63.9) | 0.305 |
| Clinical presentation | ||||||
| Systolic blood pressure (median mmHg, IQR) | 150 (135–168) | 148 (131–168) | 0.789 | 150 (132–169) | 149 (136–154) | 0.495 |
| Diastolic blood pressure (median mmHg, IQR) | 80 (70–90) | 80 (66–90) | 0.078 | 80 (70–90) | 80 (65–90) | 0.416 |
| NIHSS (median, IQR) | 0 (0–1) | 0 (0–1) | 0.270 | 0 (0–1) | 0 (0–0.75) | 0.097 |
| Duration of symptoms | 0.020 | 0.012 | ||||
| < 10 min | 107 (15.5) | 31 (25.6) | 126 (16.2) | 12 (33.3) | ||
| < 60 min | 163 (23.6) | 28 (23.1) | 181 (23.3) | 10 (27.8) | ||
| > 60 min | 421 (60.9) | 62 (51.2) | 469 (60.4) | 14 (38.9) | ||
| Co-morbidities | ||||||
| Arterial hypertension (n, %) | 551 (79.7) | 106 (87.6) | 0.042 | 625 (80.5) | 32 (88.9) | 0.213 |
| Hyperlipidaemia (n, %) | 590 (85.4) | 108 (89.3) | 0.258 | 663 (85.4) | 35 (97.2) | 0.047 |
| Atrial fibrillation (n, %) | 148 (21.4) | 29 (24.0) | 0.531 | 174 (22.4) | 3 (8.3) | 0.045 |
| Diabetes mellitus (n, %) | 166 (24) | 29 (24) | 0.989 | 187 (24.1) | 8 (22.2) | 0.797 |
| Obesity (n, %) | 119 (17.2) | 26 (21.5) | 0.258 | 134 (17.3) | 11 (30.6) | 0.042 |
| Coronary heart disease (n, %) | 97 (14) | 31 (25.6) | 0.001 | 121 (15.6) | 7 (19.4) | 0.535 |
| Heart failure (n, %) | 91 (13.2) | 18 (14.9) | 0.611 | 104 (13.4) | 5 (13.9) | 0.933 |
| History of myocardial infarction (n, %) | 48 (6.9) | 20 (16.5) | < 0.001 | 6.4 (8.2) | 4 (11.1) | 0.544 |
| Aortic valve stenosis (n, %) | 38 (5.5) | 8 (6.6) | 0.625 | 44 (5.7) | 2 (5.6) | 0.977 |
| Chronic kidney disease (n, %) | 104 (15.1) | 22 (18.2) | 0.380 | 120 (15.5) | 6 (16.7) | 0.846 |
| PFO (n, %) | 119 (17.2) | 15 (12.4) | 0.187 | 130 (16.8) | 4 (11.1) | 0.373 |
| PFO + atrial aneurysm (n, %) | 23 (3.3) | 0 (0) | 0.042 | 23 (3) | 0 (0) | 0.295 |
| Pulmonal embolism (n, %) | 8 (1.2) | 2 (1.7) | 0.649 | 23 (3) | 0 (0) | 0.295 |
| History of cancer (n, %) | 74 (10.7) | 13 (10.7) | 0.991 | 84 (10.8) | 3 (8.3) | 0.637 |
| History of ischemic stroke (n, %) | 137 (19.8) | 33 (27.3) | 0.063 | 162 (20.9) | 8 (22.2) | 0.846 |
| TIA within the last seven days (n, %) | 85 (12.3) | 20 (16.5) | 0.201 | 96 (12.4) | 9 (25.0) | 0.027 |
| Medication | ||||||
| Antiplatelet medication (n, %) | 250 (36.2) | 70 (57.9) | < 0.001 | 299 (38.5) | 21 (58.3) | 0.017 |
| Dual antiplatelet medication (n, %) | 15 (2.2) | 10 (8.3) | < 0.001 | 24 (3.1) | 1 (2.8) | 0.915 |
| NOAK (n, %) | 50 (7.2) | 8 (6.6) | 0.806 | 56 (7.2) | 2 (5.6) | 0.705 |
| Marcumar (n %) | 66 (9.6) | 14 (11.6) | 0.429 | 78 (10.1) | 2 (5.6) | 0.376 |
| Antihypertensive medication (n, %) | 508 (73.5) | 100 (82.6) | 0.033 | 578 (74.5) | 30 (83.3) | 0.231 |
| Antihyperlipidemic medication (n, %) | 246 (35.6) | 69 (57) | < 0.001 | 295 (38) | 20 (55.6) | 0.035 |
SD Standard deviation, IQR Interquartile range, NIHSS National Institute of Health Stroke Scale, PFO Persistent foramen ovale, TIA Transient ischemic attack, NOAK New oral anticoagulant
Transient ischemic attack scores in patients with- and without ipsilateral vascular pathology and the need for invasive treatment
| TIA Scores | No ipsilateral vascular pathology ( | Ipsilateral vascular pathology ( | No invasive treatment ( | Invasive treatment (n = 36) | ||
|---|---|---|---|---|---|---|
| ABCD2-Score (median, IQR) | 4 (3–5) | 4 (3–5) | 0.478 | 4 (3–5) | 4 (3–5) | 0.941 |
| ABCD3-Score (median, IQR) | 4 (3–6) | 5 (3–6) | 0.757 | 4 (3–6) | 5 (3.25–6) | 0.287 |
| SPI-II (median, IQR) | 3 (0–5) | 3 (1–6) | 0.142 | 3 (1–5) | 2.5 (0.25–5) | 0.703 |
TIA Transient ischemic attack, IQR Interquartile range, SPI-II Stroke prognosis instrument
Multivariate logistic regression models including predictors for ipsilateral vascular pathologies and the need for invasive treatment in patients with transient ischemic attack
| Regression coefficient | OR | 95%CI | ||
|---|---|---|---|---|
| Ipsilateral vascular pathology (model excluding presenting symptoms) | ||||
| Sex, male | 0.457 | 1.579 | 1.049–2.377 | 0.029 |
| Duration of Symptoms | −0.368 | 0.692 | 0.542–0.884 | 0.003 |
| Arterial Hypertension | 0.541 | 1.718 | 0.951–3.104 | 0.073 |
| Coronary heart disease | 0.650 | 1.916 | 1.184–3.101 | 0.008 |
| Intercept | −1.723 | 0.179 | < 0.001 | |
| Ipsilateral vascular pathology (model including presenting symptoms) | ||||
| Sex, male | 0.433 | 1.542 | 1.023–2.326 | 0.039 |
| Duration of Symptoms | −0.402 | 0.669 | 0.522–0.857 | 0.001 |
| Arterial Hypertension | 0.561 | 1.753 | 0.968–3.173 | 0.064 |
| Coronary heart disease | 0.662 | 1.939 | 1.196–3.145 | 0.007 |
| Vertigo | 0.462 | 1.587 | 1.001–2.516 | 0.049 |
| Intercept | −1.751 | 0.174 | < 0.001 | |
| Need for invasive treatment (model excluding presenting symptoms) | ||||
| Duration of symptoms | −0.570 | 0.565 | 0.378–0.846 | 0.006 |
| Arterial Hypertension | 0.960 | 2.612 | 0.895–7.621 | 0.079 |
| Hyperlipidaemia | 1.737 | 5.681 | 0.766–42.117 | 0.089 |
| Atrial fibrillation | −1.293 | 0.274 | 0.082–0.917 | 0.036 |
| Intercept | −4.023 | 0.018 | 0.001 | |
| Need for invasive treatment (model including presenting symptoms) | ||||
| Duration of symptoms | −0.600 | 0.549 | 0.363–0.892 | 0.004 |
| Arterial Hypertension | 0.971 | 2.639 | 0.896–7.774 | 0.078 |
| Hyperlipidaemia | 1.761 | 5.821 | 0.781–43.363 | 0.086 |
| Atrial fibrillation | −1.323 | 0.266 | 0.079–0.901 | 0.033 |
| Dysarthria | −1.135 | 0.321 | 0.096–1.078 | 0.066 |
| Hemiparesis | 0.978 | 2.659 | 1.325–5.337 | 0.006 |
| Intercept | −4.243 | 0.014 | < 0.001 | |
OR Odds ratio, CI Confidence interval